Combination of dextromethorphan and memantine in treating bipolar spectrum disorder: a 12-week double-blind randomized clinical trial.
Sheng-Yu LeeTzu-Yun WangShiou-Lan ChenYun-Hsuan ChangPo-See ChenSan-Yuan HuangNian-Sheng TzengLiang-Jen WangI-Hui LeeKao-Ching ChenYen-Kuang YangJau-Shyong HongRu-Band LuPublished in: International journal of bipolar disorders (2020)
We concluded that add-on DM30 + MM5 was significantly more effective than placebo for clinical symptoms and plasma BDNF levels. Additional studies with larger samples and mechanistic studies are necessary to confirm our findings. Trial registration NCT03039842 (https://register.clinicaltrials.gov/). Trial date was from 1 Jan 2013 to 31 December 2016 in National Cheng Kung University Hospital. Registered 28 February 1 2017-Retrospectively registered, https://clinicaltrials.gov/ct2/show/NCT03039842?term=NCT03039842&rank=1.
Keyphrases
- phase iii
- double blind
- placebo controlled
- phase ii
- study protocol
- clinical trial
- spectrum disorder
- open label
- case control
- computed tomography
- preterm infants
- randomized controlled trial
- bipolar disorder
- quality improvement
- image quality
- magnetic resonance imaging
- contrast enhanced
- metabolic syndrome
- gestational age
- insulin resistance